Iradimed Co (IRMD)vsNovartis AG ADR (NVS)
IRMD
Iradimed Co
$82.22
+0.43%
HEALTHCARE · Cap: $1.07B
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 65564% more annual revenue ($56.69B vs $86.34M). IRMD leads profitability with a 26.7% profit margin vs 22.5%. NVS appears more attractively valued with a PEG of 3.22. NVS earns a higher WallStSmart Score of 51/100 (C-).
IRMD
Hold48
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.7%
Fair Value
$61.47
Current Price
$82.22
$20.75 premium
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Keeps 27 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Trading at 10.3x book value
0.3% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 26.7% and operating margin at 31.2%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Revenue Growth, Market Cap. A P/E of 47.2x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
IRMD carries more volatility with a beta of 0.90 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 48/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?